Point Therapeutics to Host Second Quarter 2006 Results Conference Call/Audio Webcast

Point Therapeutics, Inc. (NASDAQ: POTP), announced today
that it will release second quarter 2006 results on Tuesday, August 8,
2006, after the close of the U.S. financial markets. A conference call
will follow at 4:30 PM Eastern Time, to review the results and provide
an update on the Company's progress.
   Participants are invited to attend the call by visiting
www.pther.com or by dialing:

   866-202-3048 (International: 617-213-8843)
   Passcode: 12632977

   A re-broadcast of the conference call will be available until
August 15, 2006 and accessible by dialing:

   888-286-8010 (International: 617-801-6888)
   Passcode: 51903272

   About Point Therapeutics, Inc.:

   Point is a Boston-based biopharmaceutical company developing a
portfolio of dipeptidyl peptidase (DPP) inhibitors for use in cancer,
type 2 diabetes and as vaccine adjuvants. Point is currently studying
its lead product candidate, talabostat, in two Phase 3 trials in
non-small cell lung cancer. Point is also studying talabostat in
several Phase 2 trials, including as a single-agent in metastatic
melanoma, in combination with cisplatin in metastatic melanoma, in
combination with rituximab in advanced chronic lymphocytic leukemia,
and in combination with gemcitabine in metastatic pancreatic cancer.
In addition, Point's portfolio includes two other DPP inhibitors in
preclinical development--PT-630 for type 2 diabetes, and PT-510 as a
vaccine adjuvant.